2,015 Shares in Intuitive Surgical, Inc. $ISRG Purchased by White Lighthouse Investment Management Inc.

White Lighthouse Investment Management Inc. purchased a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 3rd quarter, HoldingsChannel reports. The fund purchased 2,015 shares of the medical equipment provider’s stock, valued at approximately $819,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. North Point Portfolio Managers Corp OH purchased a new position in Intuitive Surgical during the 3rd quarter worth approximately $27,000. Main Street Group LTD acquired a new stake in Intuitive Surgical during the 1st quarter valued at $30,000. Compass Financial Management LLC purchased a new stake in shares of Intuitive Surgical in the second quarter valued at $30,000. Vermillion Wealth Management Inc. lifted its holdings in shares of Intuitive Surgical by 58.1% in the first quarter. Vermillion Wealth Management Inc. now owns 68 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 25 shares in the last quarter. Finally, Evergreen Advisors LLC purchased a new stake in shares of Intuitive Surgical in the first quarter valued at $35,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Mark Brosius sold 77 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $375.57, for a total value of $28,918.89. Following the transaction, the executive vice president directly owned 881 shares of the company’s stock, valued at approximately $330,877.17. This represents a 8.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Ladd sold 400 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the sale, the director owned 251 shares of the company’s stock, valued at approximately $95,129. This represents a 61.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,370 shares of company stock worth $4,891,989 over the last 90 days. 0.60% of the stock is currently owned by insiders.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q3 revenue increased 21.7% year over year to $3.05 billion, surpassing the $2.91 billion consensus estimate, while adjusted earnings of $3.00 per share exceeded expectations of approximately $2.65. Intuitive Surgical Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Underlying demand remained healthy: worldwide procedures grew approximately 15%, including about 14% growth in da Vinci procedures and 31% growth in Ion procedures. System placements also rose to 546 from 427 a year earlier. Intuitive Announces Third Quarter Earnings
• Positive Sentiment: Several analysts maintained bullish views or raised targets following the report, including JPMorgan, which lifted its target to $475 and kept an Overweight rating, while Bank of America reiterated Buy with a $470 target. Intuitive Surgical Buy Rating Reaffirmed

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $428.12 on Thursday. The firm has a market cap of $151.25 billion, a PE ratio of 51.77, a P/E/G ratio of 3.30 and a beta of 1.46. The firm’s 50 day moving average price is $393.50 and its two-hundred day moving average price is $408.89. Intuitive Surgical, Inc. has a twelve month low of $328.57 and a twelve month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.35. The company had revenue of $3.05 billion during the quarter, compared to the consensus estimate of $2.91 billion. Intuitive Surgical had a net margin of 25.54% and a return on equity of 17.70%. The company’s revenue was up 21.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.40 EPS. Equities analysts anticipate that Intuitive Surgical, Inc. will post 8.87 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Robert W. Baird lifted their price target on Intuitive Surgical from $513.00 to $550.00 and gave the company an “outperform” rating in a report on Wednesday. Wells Fargo & Company reissued an “overweight” rating and issued a $486.00 price objective (down from $487.00) on shares of Intuitive Surgical in a research note on Wednesday. Erste Group Bank raised Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Wednesday. BMO Capital Markets restated an “outperform” rating on shares of Intuitive Surgical in a research report on Monday, July 20th. Finally, BNP Paribas Exane raised Intuitive Surgical to an “outperform” rating in a research note on Tuesday, July 28th. Twenty-five analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $500.13.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.